Ranbaxy’s First Biosimilar Target Will Be Amgen’s Neupogen
This article was originally published in The Pink Sheet Daily
Executive Summary
Ranbaxy is partnered with another Indian drug maker, Zenotech, in its foray into biosimilar development.
You may also be interested in...
Ranbaxy Strengthens Ties With Injectables Specialist Zenotech
Expanded investment will help Ranbaxy’s position in the specialty sector, firm says; the two Indian companies have already collaborated on development of a biosimilar.
Ranbaxy Strengthens Ties With Injectables Specialist Zenotech
Expanded investment will help Ranbaxy’s position in the specialty sector, firm says; the two Indian companies have already collaborated on development of a biosimilar.
Dr. Reddy's Launches Rituxan Generic
Dr. Reddy's Laboratories launched the first follow-on biologic of the non-Hodgkin's lymphoma treatment rituximab on April 30, the company announced